New mitochondrial disease identified in identical twins
Unlike other mitochondrial diseases, a newly discovered form leads to hyperactive mitochondria, causing patients to have low body weight despite excessive food intake.
List view / Grid view
Unlike other mitochondrial diseases, a newly discovered form leads to hyperactive mitochondria, causing patients to have low body weight despite excessive food intake.
Sino Biological’s “FucoFree” eukaryotic expression system provides high-yield and high-throughput afucosylated monoclonal antibody (mAb) production.
The scientists found the mechanism of drug resistance depends on activation of a protein called KDM1B which controls and regulates gene expression.
In a petri dish under an environmental condition reminiscent of ALS, the team found that the protein activates a unique pathway inside cells that increases survival and protects endothelial cells from toxic substances in the blood.
A Boston University researcher has been granted funding for the development pre-clinical models to test potential Nipah virus vaccines.
12 October 2022 | By Unchained Labs
Watch this on-demand webinar to see first-hand data results demonstrating the power and flexibility of Unagi for nucleic acids, LNPs and AAVs.
A potential Zika virus vaccine, developed by deleting part of the Zika genome that codes for the viral shell, was effective and safe in mice.
Researchers at the University of Arizona Health Sciences found that CD4 plays an active role in regulating T-cell receptor signalling.
This whitepaper reviews the drug discovery progress for neurodegenerative diseases, focusing on promising candidates identified using iPSC technology.
Deleting the gene POU2AF2 kills cancer cells in deadly subtype of small-cell lung cancer.
Victoria Rees and Ria Kakkad from Drug Target Review bring you the key takeaways from the ELRIG Drug Discovery 2022 event in London.
Potential uses for the study could include repairing spinal cord injuries and a range of other localised injection applications.
Researchers say a newly developed lab technique could spark a “paradigm shift” in biopharmaceuticals testing, promising to speed up drug discovery and development of protein-based drugs.
A capsule that tunnels through mucus in the gastrointestinal tract could be used to orally administer large protein drugs such as insulin.
Researchers have discovered a protein, Ait1, that is responsible for controlling cell growth in yeasts. Since humans and yeasts have remarkably similar cellular mechanisms, teasing out the differences presents drug developers with new target.